The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Novel targets being explored in multiple myeloma and the value of CELMoDs
Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses novel targets being explored in multiple myeloma, including FcRH5 and CD38, and further comments on the excitement surrounding the CELMoDs iberdomide and mezigdomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar
